Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antihistamines in Ocular Allergy: Are They All Created Equal?

Antihistamines in Ocular Allergy: Are They All Created Equal? Use of topical antihistamines in the treatment of allergic conjunctivitis has evolved over the past several decades as our knowledge of the nature of the underlying disease has progressed. Formulations for the eye typically employ H1-receptor antagonists with a dual action, both directly as competitors for histamine receptor occupancy and as mast cell–stabilizing agents. Many of these compounds also display activity against late-phase allergic symptoms. Of the newest available drugs, several have a prolonged duration of action allowing once-daily dosing. Future development is likely to focus on long-acting agents such as these and on drugs that can target additional histamine receptor subtypes. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Allergy and Asthma Reports Springer Journals

Antihistamines in Ocular Allergy: Are They All Created Equal?

Loading next page...
 
/lp/springer-journals/antihistamines-in-ocular-allergy-are-they-all-created-equal-dFy7hGdnKA

References (70)

Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Allergology
ISSN
1529-7322
eISSN
1534-6315
DOI
10.1007/s11882-011-0188-5
pmid
21437647
Publisher site
See Article on Publisher Site

Abstract

Use of topical antihistamines in the treatment of allergic conjunctivitis has evolved over the past several decades as our knowledge of the nature of the underlying disease has progressed. Formulations for the eye typically employ H1-receptor antagonists with a dual action, both directly as competitors for histamine receptor occupancy and as mast cell–stabilizing agents. Many of these compounds also display activity against late-phase allergic symptoms. Of the newest available drugs, several have a prolonged duration of action allowing once-daily dosing. Future development is likely to focus on long-acting agents such as these and on drugs that can target additional histamine receptor subtypes.

Journal

Current Allergy and Asthma ReportsSpringer Journals

Published: Mar 25, 2011

There are no references for this article.